Waldenstrom macroglobulinaemia with <scp>AA</scp> amyloidosis reveals a B‐cell‐restricted <i>NLRP2</i> variant-Reference-Cited by-同舟云学术

Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B‐cell‐restricted NLRP2 variant

Published:2024-03-10 Issue:5 Volume:204 Page:2117-2120
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Terré Alexandre¹²^ORCID,Buob David³,Cez Alexandre⁴,Rodero Mathieu P.⁵,Georgin‐Lavialle Sophie¹

Affiliation:

1. Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA amyloidosis Assistance Publique‐Hôpitaux de Paris, Tenon Hospital, Sorbonne University Paris France

2. Laboratoire Mécanismes Cellulaires et Moléculaires des Désordres Hématologiques et Implications Thérapeutiques Université Paris Cité, Inserm, Institut Imagine Paris France

3. Department of Pathology Assistance Publique‐Hôpitaux de Paris, Tenon Hospital, Sorbonne University Paris France

4. Department of Nephrology and Dialysis Assistance Publique‐Hôpitaux de Paris, Hôpital Tenon Paris France

5. Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Université Paris Cité, CNRS Paris France

Funder

Institut des maladies génétiques Imagine

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19383

Reference14 articles.

1. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

2. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia

3. Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients

4. AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of “monoclonal gammopathy of inflammatory significance”?

5. AA Amyloidosis: Pathogenesis and Targeted Therapy